Dark Pharma · DP-041
The Key Trial Site Enrolled Patients Who Didn't Exist. The Drug Was Approved Anyway.
Aventis's approval of the antibiotic Ketek was undermined by fabricated patient data from a physician later convicted of fraud. Despite serious concerns from FDA medical reviewer David Ross, Ketek received approval in 2004, eventually linked to cases of severe liver failure.
Case Assets
The Case Debrief is free to view. Full Case Study, Teaching Notes, Slide Deck, Discussion Guide, and Assessment are available with a Premium subscription.
Brief the Board
PREMIUM
🔒 Unlock
Learn the Case
FREE — included
Study the Case
PREMIUM
🔒 Unlock
Teach the Case
PREMIUM
🔒 Unlock
Present the Case
PREMIUM
🔒 Unlock
Run a Team Discussion
PREMIUM
🔒 Unlock
Test Your Judgement
PREMIUM
🔒 Unlock
Watch the Full Episode
The complete cinematic audio documentary — Dark Pharma
Unlock the Full Case Library
Get every Case Study, Slide Deck, Teaching Notes, Discussion Guide, and Assessment — across a growing library of business cases.
View Pricing →Related Cases
Cases that share a governance or behavioural model with this one.
The Raid
HJ-016
He stopped the biggest defence merger in history. $11.6 billion. He ke...
Shared: Risk Assessment Framework, Independent Oversight, Whistleblower Protection
Dark Pharma
DP-042
The Internal Data Showed The Weight Gain. The Marketing Said Something...
Shared: Transparency Protocol, Whistleblower Protection
Dark Capital
DC-053
HE FILED THE REPORT EVERY QUARTER. THE POSITION WAS 5% OF WORLD SUPPLY...
Shared: Independent Oversight, Whistleblower Protection
Dark Law
DL-020
HE PAID THE OFFICIAL IN CASH. THE DRUG WAS APPROVED IN WEEKS. HE KEPT ...
Shared: Transparency Protocol, Whistleblower Protection